医学
Golimumab公司
强直性脊柱炎
内科学
脊柱炎
疾病
儿科
梅德林
外科
物理疗法
标识
DOI:10.1097/rhu.0000000000002365
摘要
In August 2022 issue of Journal of Clinical Rheumatology, the article “Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study” requires correction. The sponsor recently became aware of data errors related to the Bath Ankylosing Spondylitis Metrology Index (BASMI) and the UCSF Enthesitis Index that occurred during the study. The ensuing tabular and in-text corrections are provided hereinafter. The corrected BASMI results are in Table 1 and in the Supplemental Digital Content 1 that are provided below. TABLE 1 - Correction. Baseline Demographics and Clinical Characteristicsa Early Disease Late Disease Placebo n=25 IV Golimumab n=35 Placebo n=28 IV Golimumab n=24 BASMI (0–10)bc 4.3 (1.4) 4.3 (1.8) 4.9 (1.3) 5.4 (1.5) Enthesitis score, UCSF (0–17)bc 5.2 (4.4) 4.7 (3.0) 6.3 (4.4) 6.6 (4.4) aMean (SD) reported unless otherwise stated.bEarly disease: placebo, n=24.cLate disease: IV golimumab, n=21. Supplemental Digital Content 1 - Correction. Mean (SD) Changes From Baseline in Additional Efficacy Outcomes Week 16 Week 52 Early Disease Late Disease Early Disease Late Disease Outcome (score range) Placebo (N=25) IV Golimumab (N=35) Placebo (N=28) IV Golimumab (N=24) Placebo→IV Golimumab (N=25) IV Golimumab (N=35) Placebo→IV Golimumab (N=28) IV Golimumab (N=24) Bath Ankylosing Spondylitis Metrology Index (0-10)b −0.3 (0.9) −0.6 (0.9) 0 (0.6) −0.6 (0.8) −0.9 (1.1) −0.7 (0.7) −0.6 (0.9) −0.5 (1.0) Enthesitis score (0-17)b −0.3 (3.2) −2.9 (2.9) −0.8 (2.8) −2.2 (3.1) −2.2 (4.2) −3.3 (2.4) −2.8 (3.0) −3.2 (5.6) bFor Week 16, early disease N=24 placebo, late disease N=28 placebo and N=21 IV golimumab; for Week 52, early disease N=24 placebo→IV golimumab, late disease N=21 IV golimumab. The corrected Enthesitis results are in the 3rd paragraph of Demographics and Baseline Disease Characteristics subsection and 3rd paragraph of Clinical Efficacy by Disease Duration Status within the Results section, Table 1, and Supplemental Digital Content 1 provided below. 3rd paragraph of Demographics and Baseline Disease Characteristics changes: When comparing baseline enthesitis in late disease, vs early disease mean enthesitis scores were updated from 5.9–6.5 vs. 4.6–4.9 to 6.3–6.6 vs. 4.7–5.2, respectively. 3rd paragraph of Clinical Efficacy by Disease Duration Status changes: The mean (SD) improvement in enthesitis from baseline to week 16 in the placebo group with early disease was updated from 0.1 [3.6] to -0.3 [3.2]. These changes are minor and do not impact our interpretation of the data or conclusions regarding the efficacy of golimumab in ankylosing spondylitis. The authors apologize for these errors.
科研通智能强力驱动
Strongly Powered by AbleSci AI